Enhertu: Know about Medication

 Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of: 

adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more anti-HER2-based regimens in the metastatic setting. 

adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously received a trastuzumab-based regimen.

Recommended Dosage: The recommended dosage of  Enhertu 100 mg Injection for Metastatic Breast Cancer and Locally Advanced or Metastatic Gastric Cancer is 5.4 mg/kg and 6.4 mg/kg respectively, administered as an intravenous infusion once every three weeks (21-day cycle) until the disease is progressive or unacceptable toxicity occurs. 

In case a planned dose is missed or delayed, administer as promptly as possible; avoid waiting until the next planned cycle. Adjust the schedule of administration in order to maintain a 3 week interval between doses. The infusion is administered at the dose and rate the patient tolerated in the most recent infusion.

Serious, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, may occur in patients treated with trastuzumab deruxtecan injection. Monitor patients for signs/symptoms of ILD. Promptly assess evidence of ILD. Evaluate patients with suspected interstitial lung disease by radiographic imaging. 

Serious neutropenia, including febrile neutropenia, may occur in patients treated with Trastuzumab Deruxtecan. Monitor complete blood counts before initiating treatment and before each dose. On behalf of the severity of neutropenia, this medicine may require dose interruption or reduction. 

Patients treated with enhertu injection may be at higher risk of having left ventricular dysfunction. LVEF needs to be assessed before initiating treatment and at regular intervals throughout the treatment. LVEF decrease needs to be managed through therapy interruption. 

Depending on its mechanism of action, enhertu can cause fetal harm if used by a pregnant woman. Pregnancy status needs to be verified prior to the initiation of treatment with this drug. Women should not breastfeed while on treatment and for 7 months after the final dose of Enhertu. 

Documentation & Availability:

What documents are required to import ENHERTU to India?

ENHERTU (fam-trastuzumab deruxtecan-nxki) can be imported by patients or GOVT hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients id proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is ENHERTU available in India?

ENHERTU (trastuzumab deruxtecan injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

On availability of enhertu in India (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore and Pune etc.)

• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

ENHERTU can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of ENHERTU (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for price of enhertu 100 mg injection price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Sourcing & Delivery:

Indian Pharma Network is able to source the ENHERTU (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

FAQs:

What is the Generic Name for the trade name drug Enhertu®?

Fam-trastuzumab Deruxtecan-nxki is Generic Name for the trade name drug Enhertu®.

Is Enhertu® approved by the FDA?

Yes, Enhertu® is approved by the FDA. Date of approval: May 4, 2022.

What is the dosage and form of Enhertu® supplied?

Enhertu® is supplied for injection: 100 mg lyophilized powder in a single-dose vial for intravenous administration. 

Does Enhertu® cause hair loss?

Yes, hair loss is the most common adverse reaction of Enhertu®. 

Is Enhertu® chemotherapy or immunotherapy?

Enhertu® is a chemotherapy and it is also a targeted therapy anti-cancer medicine. 

What are the most common side effects due to Enhertu®? 

Most common side effects due to Enhertu® in patients with breast cancer were nausea, WBC count decreased, fatigue, vomiting, alopecia, platelet count decreased, constipation, decreased appetite, anemia, hypokalemia, diarrhea, and cough.

Most common side effects in patients with gastric cancer were nausea, decreased appetite, anemia, fatigue, blood alkaline phosphatase increased, alanine aminotransferase 

increased, hypokalemia, diarrhea, vomiting, constipation, pyrexia, blood bilirubin increased, and alopecia. 

How much does Enhertu® cost in India?

The enhertu cost in India is reasonable. To procure this breast and stomach cancer medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Enhertu®?

Store vials of Enhertu in a refrigerator at 2-8°C (36-46°F) in the original carton in order to protect from light until time of reconstitution. Avoid freezing. Avoid shaking the reconstituted or diluted solution. 

What are the Highlights of prescribing information for Enhertu®?

Click Here to download full Enhertu prescribing information.

Source - https://bit.ly/3orFBpk